Abstract

Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection against SIV and HIV. Persistent, recombinant herpes viruses are being used in monkeys to try to match the degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been promising but the absence of anti-Env antibody responses from the recombinant herpes viruses has been a glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the promise of this approach.

Public Health Relevance

The proposed experiments will allow a greater appreciation of the potential for recombinant herpes viruses in particular, and persistent vectors in general, for their capacity to provide protection against AIDS virus exposure. If shown to be significantly better than other vaccine approaches, it will shape the emphasis for ongoing preclinical vaccine discovery research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI063928-08
Application #
8588888
Study Section
HIV/AIDS Vaccines Study Section (VACC)
Program Officer
Pensiero, Michael N
Project Start
2004-12-01
Project End
2017-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$477,228
Indirect Cost
$166,330

  Institution

Name
University of Miami School of Medicine
Department
Pathology
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146

  Publications

Großkopf, Anna K; Ensser, Armin; Neipel, Frank et al. (2018) A conserved Eph family receptor-binding motif on the gH/gL complex of Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus. PLoS Pathog 14:e1006912
Shin, Young C; Bischof, Georg F; Lauer, William A et al. (2018) A recombinant herpesviral vector containing a near-full-length SIVmac239 genome produces SIV particles and elicits immune responses to all nine SIV gene products. PLoS Pathog 14:e1007143
Martins, Mauricio A; Tully, Damien C; Pedreño-Lopez, Núria et al. (2018) Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication. J Virol 92:
Bischof, Georg F; Magnani, Diogo M; Ricciardi, Michael et al. (2017) Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys. J Virol 91:
Bischof, G F; Shin, Y C; Fuchs, S P et al. (2017) Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. Gene Ther 24:487-492
Martins, Mauricio A; Tully, Damien C; Shin, Young C et al. (2017) Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque. AIDS Res Hum Retroviruses 33:843-858
Martins, Mauricio A; Shin, Young C; Gonzalez-Nieto, Lucas et al. (2017) Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathog 13:e1006529
Shin, Young C; Bischof, Georg F; Lauer, William A et al. (2015) Importance of codon usage for the temporal regulation of viral gene expression. Proc Natl Acad Sci U S A 112:14030-5
Hahn, Alexander S; Desrosiers, Ronald C (2014) Binding of the Kaposi's sarcoma-associated herpesvirus to the ephrin binding surface of the EphA2 receptor and its inhibition by a small molecule. J Virol 88:8724-34
Hahn, Alexander S; Desrosiers, Ronald C (2013) Rhesus monkey rhadinovirus uses eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog 9:e1003360

Showing the most recent 10 out of 13 publications